Corcept Therapeutics Incorporated (CORT)
Stock analysis · NASDAQ · Healthcare · Medical - Pharmaceuticals
Corcept Therapeutics Incorporated (CORT) is a publicly traded company in the Healthcare sector. Trailing PE 168.44. Sign in to Stocks360 for full DCF valuation, fundamentals, technicals, and AI-driven analysis.
Get full analysis → Short-Term Analysis →1-Year Price
Earnings
Proprietary Signals
About Corcept Therapeutics Incorporated
Corcept Therapeutics Incorporated, founded in 1998 and headquartered in Menlo Park, California, is a pharmaceutical firm dedicated to the discovery, development, and commercialization of treatments for serious metabolic, oncological, and neuropsychiatric disorders across the United States. Its primary commercial offering is Korlym (mifepristone) tablets, an oral medication taken once daily. Korlym is prescribed for adult patients diagnosed with endogenous Cushing's syndrome who suffer from hyperglycemia due to hypercortisolism, particularly those with type 2 diabetes or glucose intolerance, and for whom surgical options have either failed or are not viable. The company's development pipeline is robust, featuring relacorilant, which is being advanced for Cushing's syndrome. It is also investigating a combination of relacorilant with nab-paclitaxel; this pairing has concluded Phase II clinical trials for advanced ovarian tumors and is additionally being studied for conditions involving cortisol excess. Furthermore, Corcept is developing distinct selective cortisol modulators for specific indications such as metastatic castration-resistant prostate cancer and antipsychotic-induced we…
Valuation
| P/E (TTM) | 168.44× |
|---|---|
| P/S (TTM) | 11.40× |
| P/B | 13.08× |
| P/FCF (TTM) | 88.55× |
| EV / EBITDA | 325.36× |
| EV / Sales | 11.27× |
| Earnings Yield | 0.59% |
| Free Cash Flow Yield | 1.13% |
Fundamentals
| Enterprise Value | $9.37B |
|---|---|
| Revenue (TTM) | $830.81M |
| Net Income (TTM) | $56.31M |
| Free Cash Flow (TTM) | $106.92M |
| Net Debt | -$101.62M |
| Working Capital | $285.87M |
| Gross Margin | 98.30% |
| Operating Margin | 0.77% |
| Net Margin | 6.61% |
| Return on Equity | 8.37% |
| Return on Invested Capital | 0.87% |
Peers
Recent News
- Corcept Reports Positive Results from Phase 2 BELLA Trial of Lifyorli® Combined with Nab-Paclitaxel and Bevacizumab in Patients with Platin…
- 2026 ADA/EASD Consensus Report Recommends Screening for Hypercortisolism in Patients with Difficult-to-Control Type 2 Diabetes
- 2026 ADA/EASD Consensus Report Recommends Screening for Hypercortisolism in Patients with Difficult-to-Control Type 2 Diabetes
- Can Lifyorli Aid Corcept's Long-Term Growth Prospects Beyond Korlym?
- Corcept Therapeutics (NASDAQ:CORT) Director Sells $1,148,100.00 in Stock
Related
Browse more tickers: sitemap